A2734

α5IA

≥98% (HPLC)

• 同義詞: 1,2,4-Triazolo[3,4-a]phthalazine, 3-(5-methyl-3-isoxazolyl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-, 3-(5-Methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methoxy-1,2,4-triazolo[3,4-a]phthalazine
• 經驗公式（希爾表示法）: C₁₇H₁₄N₈O₂
• CAS號碼: 215874-86-5
• 分子量：: 362.35
• MDL號碼: MFCD09832717
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329770794
• NACRES: NA.77

屬性

• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: off-white to light yellow
• 溶解度: DMSO: >2 mg/mL
• 起源: Merck & Co., Inc., Kenilworth, NJ, U.S.
• 儲存溫度: 2-8°C
• SMILES 字串: Cc1cc(no1)-c2nnc3c4ccccc4c(OCc5cn(C)nn5)nn23
• InChI: 1S/C17H14N8O2/c1-10-7-14(22-27-10)16-20-19-15-12-5-3-4-6-13(12)17(21-25(15)16)26-9-11-8-24(2)23-18-11/h3-8H,9H2,1-2H3
• InChI 密鑰: NZMJFRXKGUCYNP-UHFFFAOYSA-N

描述

生化／生理作用

α5IA is a selective inverse agonist for Α5 subtype of GABAA receptor with a higher intrinsic activity at the A5 subtype than other drugs. α5IA enhances cognition in laboratory animals without being proconvulsant or anxiogenic. α5IA acts as an "alcohol antagonist," markedly reducing the amnesic effect of alcohol and partially attenuating sedation, similar to Ro15-4513, but without the anxiogenic effect. α5IA offers promise as a tool to study cognitive disorders, memory function, and treatment of alcohol-related disorders.

特點和優勢

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全資訊

• 儲存類別代碼: 13 - Non Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Gloves, type N95 (US)